Insider Selling: Globus Medical (NYSE:GMED) Director Sells $425,000.00 in Stock

Globus Medical, Inc. (NYSE:GMED) Director Ann Rhoads sold 5,000 shares of the stock in a transaction dated Wednesday, November 4th. The shares were sold at an average price of $85.00, for a total transaction of $425,000.00. Following the transaction, the director directly owned 35,384 shares of the company’s stock, valued at $3,007,640. This trade represents a 12.38% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Globus Medical Price Performance

Shares of Globus Medical stock traded down $5.97 during trading on Thursday, reaching $81.13. 4,075,147 shares of the stock traded hands, compared to its average volume of 1,481,982. The company has a market capitalization of $10.89 billion, a price-to-earnings ratio of 20.75, a P/E/G ratio of 1.28 and a beta of 0.98. The business has a fifty day simple moving average of $77.48 and a two-hundred day simple moving average of $83.35. Globus Medical, Inc. has a 52-week low of $60.36 and a 52-week high of $101.40.

Globus Medical (NYSE:GMED) last posted its earnings results on Thursday, November 5th. The medical device company reported $1.23 EPS for the quarter, topping analysts’ consensus estimates of $1.20 by $0.03. The company had revenue of $763.72 million for the quarter, compared to the consensus estimate of $792.39 million. Globus Medical had a return on equity of 14.57% and a net margin of 17.02%. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, research analysts predict that Globus Medical, Inc. will post 4.99 earnings per share for the current fiscal year.

Key Globus Medical News

Here are the key news stories impacting Globus Medical this week:

• Positive Sentiment: Third-quarter adjusted earnings were $1.23 per share, above the $1.20 consensus and up from $1.18 a year earlier. The company also increased its share-repurchase authorization by $500 million, which could support shareholder returns. Third-quarter results and repurchase announcement
• Neutral Sentiment: Globus Medical’s acquisition of Synaptive Medical expands its presence in cranial neurosurgery. The strategic opportunity may broaden its technology portfolio, though the supplied reports do not quantify the deal’s expected financial contribution. Synaptive Medical acquisition
• Negative Sentiment: Quarterly revenue of $763.7 million missed analysts’ $792.4 million estimate. The company’s FY 2026 revenue outlook of $3.1 billion also came in below the $3.2 billion consensus, tempering the positive EPS surprise. Full-year EPS guidance of $4.95–$5.05 was broadly in line with the $5.00 consensus. Quarterly results and guidance

Analyst Ratings Changes

GMED has been the topic of a number of research reports. Stifel Nicolaus reduced their price objective on Globus Medical from $95.00 to $80.00 and set a “hold” rating on the stock in a research note on Wednesday, July 8th. UBS Group started coverage on Globus Medical in a research report on Tuesday, July 28th. They set a “neutral” rating and a $82.00 target price for the company. Weiss Ratings reissued a “hold (c+)” rating on shares of Globus Medical in a report on Friday, October 9th. BTIG Research reissued a “neutral” rating on shares of Globus Medical in a report on Friday, September 18th. Finally, Royal Bank Of Canada reduced their price target on shares of Globus Medical from $115.00 to $85.00 and set an “outperform” rating on the stock in a research report on Thursday, October 1st. Three analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $99.46.

Institutional Investors Weigh In On Globus Medical

Several large investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC raised its position in Globus Medical by 4.5% during the first quarter. Janus Henderson Group PLC now owns 7,623,095 shares of the medical device company’s stock valued at $656,831,000 after purchasing an additional 328,217 shares during the period. Sculptor Capital LP raised its holdings in Globus Medical by 1.9% during the 1st quarter. Sculptor Capital LP now owns 3,058,000 shares of the medical device company’s stock valued at $263,477,000 after buying an additional 58,000 shares during the period. Allspring Global Investments Holdings LLC lifted its position in Globus Medical by 14.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,797,215 shares of the medical device company’s stock worth $133,731,000 after buying an additional 225,534 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Globus Medical by 2.0% in the first quarter. Dimensional Fund Advisors LP now owns 1,769,897 shares of the medical device company’s stock worth $152,474,000 after buying an additional 33,976 shares during the last quarter. Finally, Boston Trust Walden Corp lifted its position in Globus Medical by 4.4% in the third quarter. Boston Trust Walden Corp now owns 1,643,143 shares of the medical device company’s stock worth $123,071,000 after buying an additional 69,782 shares during the last quarter. 95.16% of the stock is owned by institutional investors.

About Globus Medical

Globus Medical, Inc develops and commercializes musculoskeletal solutions for surgeons, hospitals and patients. The company focuses primarily on spinal, orthopedic trauma and other orthopedic procedures, offering implants, instruments and related technologies designed to support surgical treatment and improve clinical outcomes.

Its product portfolio includes spinal implants and enabling technologies, including the ExcelsiusGPS robotic navigation platform and Excelsius3D imaging system.